Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis

Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial

(2016) LY Dirix et al.   CANCER RESEARCH

PD-L1 expression in tumour buds of colorectal carcinoma

(2016) Friedrich Prall et al.   HISTOPATHOLOGY

Prognostic significance of PD-L1 and PD-L2 in breast cancer

(2016) Mauricio Z. Baptista et al.   HUMAN PATHOLOGY

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

(2016) Rita Nanda et al.   JOURNAL OF CLINICAL ONCOLOGY

Latent Tuberculosis in Pregnancy: A Systematic Review

(2016) Isabelle Malhamé et al.   PLoS One

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

New Strategies in Bladder Cancer: A Second Coming for Immunotherapy

(2015) A. Ghasemzadeh et al.   CLINICAL CANCER RESEARCH

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma

(2015) Kathleen M. Mahoney et al.   CLINICAL THERAPEUTICS

Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy

(2015) Andrew B Sharabi et al.   LANCET ONCOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

PD-L1 expression is common and indicates poor prognosis

(2015) Clemens Thoma   Nature Reviews Urology

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment

(2015) G. K. Pennock et al.   ONCOLOGIST

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

(2015) Ninh M. La-Beck et al.   PHARMACOTHERAPY

Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis

(2015) Anyuan Zhong et al.   OncoTargets and Therapy

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication

(2015) O. A. Ali et al.   Cancer Immunology Research

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

(2014) S. Muenst et al.   BREAST CANCER RESEARCH AND TREATMENT

Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type

(2014) Z. Gatalica et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy

(2014) Kim A Reiss et al.   Immunotherapy

First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status

(2014) N.A. Rizvi et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

The primary microbial pathogens associated with premature rupture of the membranes in China: A systematic review

(2014) Li-nan Zeng et al.   Taiwanese Journal of Obstetrics & Gynecology

Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and elaboration

(2014) Jan P. Vandenbroucke et al.   International Journal of Surgery

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2013) Alessandro Liberati   ANNALS OF INTERNAL MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Quantitative In Situ Measurement of Estrogen Receptor mRNA Predicts Response to Tamoxifen

(2012) Jennifer M. Bordeaux et al.   PLoS One

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Regulatory T cells: how do they suppress immune responses?

(2009) S. Sakaguchi et al.   INTERNATIONAL IMMUNOLOGY

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

(2008) C A Crane et al.   ONCOGENE